Product Details

Artemether + Lumefantrine Tablets BP 140 mg deliver a high-quality combination antimalarial therapy that meets British Pharmacopoeia (BP) standards. This fixed-dose combination manages uncomplicated Plasmodium falciparum malaria, combining fast-acting and long-acting antimalarial mechanisms in a single uncoated tablet.

The tablets combine:

• Artemether, an artemisinin derivative that rapidly reduces parasite biomass by generating free radicals that damage the malaria parasite’s membrane structures, and
• Lumefantrine, an antimalarial partner drug that clears residual parasites and prevents recrudescence by disrupting parasite membrane function, providing longer-acting protection.

Doctors and health programs commonly prescribe this combination as an artemisinin-based combination therapy (ACT) for uncomplicated falciparum malaria, one of the most widely used first-line ACT regimens globally. Hospitals, clinics, and pharmacies rely on this formulation for its consistent quality and dependable therapeutic results. Our manufacturing process follows strict quality standards to guarantee high purity, accurate dosing, and reliable therapeutic efficacy in every batch.

Key Features

• BP-standard compliant combination antimalarial therapy
• Treats uncomplicated Plasmodium falciparum malaria
• Delivers fast-acting and long-acting antimalarial action
• Contains Artemether 20 mg + Lumefantrine 120 mg per uncoated tablet
• Maintains a high-purity, stable formulation
• Uses hygienic blister packaging for safe storage
• Suits hospital, clinical, and pharmacy use